Metabolic / Mitochondrial Research Peptides Guide

The Metabolic / Mitochondrial category encompasses peptides that play significant roles in cellular metabolism and mitochondrial health. These peptides have garnered attention for their potential therapeutic applications in conditions such as obesity, metabolic syndrome, and age-related degeneration. This guide highlights three key peptides: MOTS-c, SS-31, and Humanin, each presenting a unique profile in terms of evidence quality and clinical development. By examining their mechanisms, safety, and regulatory status, this guide aims to facilitate a deeper understanding of their research landscape and implications for future studies.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide that has emerged as a metabolic regulator, primarily through its activation of AMP-activated protein kinase (AMPK). Discovered in 2015 by Lee et al., MOTS-c has demonstrated promising effects in preclinical models, including the prevention of diet-induced obesity and insulin resistance in murine studies. Notably, aged mice exhibited enhanced exercise capacity, running twice as long on treadmill tests compared to controls. While a modified analog, CB4211, has shown tolerability in Phase 1 trials, native MOTS-c has yet to undergo human clinical trials. The current evidence base is rated as D, reflecting the absence of completed human studies, and underscores the need for further research to validate its metabolic applications.

SS-31, also known as Elamipretide, is a tetrapeptide designed to target mitochondria, specifically binding to cardiolipin within the inner mitochondrial membrane. This binding stabilizes the structure of cristae, which is crucial for mitochondrial function. Approved by the FDA as Forzinity in September 2025 for Barth syndrome, SS-31 has also been investigated in multiple Phase II trials addressing heart failure, renal dysfunction, and age-related macular degeneration. The evidence quality for SS-31 is rated A, reflecting robust clinical trials that support its efficacy and safety profile. As research continues, SS-31 holds promise not only in the treatment of mitochondrial diseases but also in broader applications related to metabolic health and aging.

Humanin is a mitochondria-derived peptide (MDP) consisting of 21-24 amino acids, encoded by the MT-RNR2 gene. Initially discovered in 2001 for its neuroprotective properties against Alzheimer's disease-related toxicity, Humanin has since revealed a broader spectrum of biological activities, including cytoprotection, anti-inflammatory effects, and metabolic regulation. Epidemiological studies indicate a correlation between circulating Humanin levels and longevity, particularly in centenarians, suggesting its potential role in age-related health. However, the current evidence quality is rated D, as no clinical trials have been completed to date. The lack of human studies highlights the necessity for further investigation to elucidate its therapeutic potential and mechanisms of action.